Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Piflufolastat→

Piflufolastat PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1423758-00-2
Molecular formula
C18H23FN4O8
Molecular weight
442.4 g/mol
Drug class
Diagnostic radiopharmaceuticalPSMA-targeted fluorine-18 PET imaging agent
Mechanism of action
A urea-based ligand binds prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells. The fluorine-18 positron-emitting radionuclide enables PET visualisation of PSMA-expressing lesions.
Indications / reported uses
  • PET imaging of PSMA-positive lesions in men with prostate cancer when metastatic disease is suspected in candidates for initial definitive therapy or recurrence is suspected due to elevated PSA.

Sources: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a00e5cbc-4fd5-4280-82ec-cd3498df4553 · https://www.cancer.gov/publications/dictionaries/cancer-drug/def/fluorine-f-18-piflufolastat

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Diagnostic radiopharmaceutical; PSMA-targeted fluorine-18 PET imaging agent

Mechanism of action

A urea-based ligand binds prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells. The fluorine-18 positron-emitting radionuclide enables PET visualisation of PSMA-expressing lesions.

General use cases

  • PET imaging of PSMA-positive lesions in men with prostate cancer when metastatic disease is suspected in candidates for initial definitive therapy or recurrence is suspected due to elevated PSA.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Piflufolastat PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Piflufolastat Permitted Daily Exposure (PDE) report (the Piflufolastat PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Piflufolastat Occupational Exposure Limit (OEL) report (the Piflufolastat OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.